Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Long-Term Deferred Tax (2017 - 2020)

Historic Long-Term Deferred Tax for Aytu Biopharma (AYTU) over the last 8 years, with Q2 2020 value amounting to $39.6 million.

  • Aytu Biopharma's Long-Term Deferred Tax rose 6973.65% to $39.6 million in Q2 2020 from the same period last year, while for Jun 2020 it was $39.6 million, marking a year-over-year increase of 6973.65%. This contributed to the annual value of $39.6 million for FY2020, which is 6973.65% up from last year.
  • According to the latest figures from Q2 2020, Aytu Biopharma's Long-Term Deferred Tax is $39.6 million, which was up 6973.65% from $23.3 million recorded in Q2 2019.
  • Over the past 5 years, Aytu Biopharma's Long-Term Deferred Tax peaked at $19369.0 billion during Q3 2017, and registered a low of $16.7 million during Q2 2018.
  • Over the past 5 years, Aytu Biopharma's median Long-Term Deferred Tax value was $31.4 million (recorded in 2019), while the average stood at $5112.3 billion.
  • Per our database at Business Quant, Aytu Biopharma's Long-Term Deferred Tax tumbled by 1368.68% in 2018 and then surged by 6973.65% in 2020.
  • Aytu Biopharma's Long-Term Deferred Tax (Quarter) stood at $11305.0 billion in 2016, then skyrocketed by 71.33% to $19369.0 billion in 2017, then crashed by 100.0% to $16.7 million in 2018, then skyrocketed by 39.38% to $23.3 million in 2019, then skyrocketed by 69.74% to $39.6 million in 2020.
  • Its last three reported values are $39.6 million in Q2 2020, $23.3 million for Q2 2019, and $16.7 million during Q2 2018.